Independent Medical Education (IME) Grants

Fibrosing Interstitial Lung Diseases (ILDs)

• IME RFP
• Preceptorship IME RFP

To view Educational Objectives and begin the process of applying for a Medical Education grant supported by the Boehringer Ingelheim Pharmaceutical Inc and Eli Lilly and Company global Alliance agreement, click here.

Pathophysiology, Prevalence, Burden of Disease

• Increase the healthcare team’s understanding of the pathophysiology, prevalence, morbidity and mortality, burden of disease, mental health impacts, and signs and symptoms of fibrosing ILDs (i.e., IPF, PPF, SARD-ILD).

Diagnosis

• Increase the healthcare team’s awareness of fibrosing ILDs (i.e., IPF, PPF, SARD ILD) to encourage earlier diagnosis and referral to appropriate specialists or specialty centers.
• Improve the healthcare team’s knowledge of updated diagnostic guidelines and recommended testing methods, such as high-resolution computed tomography, and interpretation.
• Increase awareness of the importance of routine assessments in patients with fibrosing ILDs (i.e., IPF, PPF, SARD-ILD) to promptly identify lung involvement, acute exacerbations, and disease progression.

Clinical Management

• Improve the healthcare team’s knowledge regarding future horizons in diagnosis, follow up, screening, management, and treatment of fibrosing ILDs (i.e., IPF, PPF, SARD-ILD) including developments in clinical research, treatment guidelines, and emerging therapies.
• Improve multidisciplinary management of the possible fibrosing ILD (i.e., IPF, PPF, SARD-ILD) risk factors and comorbidities.
• Improve effective communication with, and education of, fibrosing ILD patients and their caregivers about their disease.

Pathophysiology:

• Improve the healthcare team's ability to diagnose Generalized Pustular Psorisis (GPP) and assess disease severity.
• Advance the healthcare team's understanding of recent pathophysiological findings in GPP that differentiates it from other conditions including plaque psoriasis.

Unmet Need/Burden of Disease:

• Improve HCP awareness of GPP as a chronic disease, as well as related comorbidities and holistic/multidisciplinary management.
• Improve effective communication with, and education of, GPP patients about their disease.

Clinical Management:

• Increase the healthcare team's understanding of clinical research related to potential current and future options for the management of adults with GPP.

Schizophrenia

Pathophysiology:

• Improve the clinician’s recognition of CIAS through continued education of the pathophysiology in cognitive impairment associated with schizophrenia (CIAS) and the differences between CIAS and negative symptoms.

Unmet Medical Needs/Burden of Disease:

• Increase the clinician’s awareness of the current unmet medical needs and heavy burden of disease in patients with cognitive impairment associated with schizophrenia (CIAS).

Clinical Management:

• Improve the clinician’s understanding of current clinical management of cognitive impairment associated with schizophrenia (CIAS), its limitations and perspectives of care pathways, as well as ongoing developments in clinical research.

Digital Therapeutics

Pathophysiology:

• Improve the clinician's understanding of the pathophysiology of symptoms in associated with schizophrenia, including negative symptoms and cognitive impairment associated with schizophrenia (CIAS), as well as the differences between those symptoms.

Unmet Medical Needs/Burden of Disease:

• Increase the clinician's awareness of the current unmet medical needs and burden of disease in patients with schizophrenia, including cognitive and negative symptoms associated with schizophrenia as well as the potential utility of digital therapeutics in psychiatry, including schizophrenia.

Clinical Management:

• Improve the clinician's understanding of the management and limitations of treating cognitive and negative symptoms of schizophrenia, as well as ongoing developments in clinical research in schizophrenia and digital therapeutics in psychiatry.

• Expand Clinician’s understanding of novel pathways that play a role in modulation of body weight and metabolic benefits extending beyond weight management (obesity related complications i.e. metabolic associated fatty liver disease (MAFLD), metabolic dysfunction-associated steatohepatitis (MASH), cardiovascular risk, type 2 diabetes, chronic kidney disease).
• Expand Clinician’s understanding of the potential role of glucagon and its receptors in the management of obesity and obesity-related complications.

Lung Cancer (NSCLC/SCLC)

• Improve clinician’s understanding of the importance of broad molecular profiling in order to identify actionable oncogenic drivers in NSCLC.
• Improve the clinician’s understanding of molecular profiling results for treatment selection in HER2 - mutated NSCLC.
• Increase clinician’s awareness around the recommended diagnosis and treatment pathways for HER2 - mutated NSCLC and developments in clinical research.
• Educate Stakeholders on the Unmet Need and Burden of illness for HER2 in NSCLC.
• Improve Stakeholder knowledge of current and future clinical landscape for NSCLC, such as HER2 and DLL3.

Sarcoma

• Increase the awareness regarding the role of MDM2 amplification in the pathogenesis of DDLPS.
• Increase the clinician’s awareness of the multi disciplinary team approach to address the complexities of early and accurate diagnosis.
• Improve the clinician’s understanding of current clinical management of dedifferentiated liposarcoma and unmet needs, as well as developments in clinical research, such as targeted therapies.
• Improve clinician’s understanding of soft tissue sarcoma and liposarcoma subtypes, particularly dedifferentiated liposarcoma.
• Educate the healthcare teams understanding of the patient/caregiver journey.

Biliary Tract Cancer (BTC)

• Educate HCPs on the early signs and symptoms of BTC.
• Increase HCP awareness around the diagnostic pathway for BTC, specifically the MDM2/p53 pathway.
• Improve HCP understanding regarding current clinical management of BTC including molecular testing and targeting MDM2 in BTC.